NCT01843127已完成1 期
A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects With Type 2 Diabetes Mellitus, Followed by An Open-label, Single Dose, Exenatide Active-control Period
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 3
- 主要终点
- Area under the concentration-time curve (AUC) of plasma glucagon during the standard meal test (SMT)
研究概览
简要总结
To explore the mechanism of action of ranolazine as a potential treatment for type 2 diabetes mellitus (T2DM).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females, 18 to 65 years old, inclusive
- •Documented history of T2DM for ≥5 years
- •Body mass index (BMI) 20.0 to 40.0 kg/m2, inclusive, at Screening
- •Stable treatment (≥ 12 weeks) with metformin alone, a sulfonylurea alone, a meglitinide alone, or a combination of metformin with either a sulfonylurea or a meglitinide
- •HbA1c ≥ 7.0% and ≤ 10.5%, inclusive, at Screening
- •Fasting glucose within specific ranges, at Screening and after 14 +/-2 days of wash-out from prior oral anti-diabetic agents
- •Fasting serum C-peptide ≥0.8 ng/mL, at Screening
- •Estimated glomerular filtration rate (eGFR)≥60 mL/min/1.73 m2
- •Ability and willingness to comply with all study procedures during the course of the study, including washout from oral anti-diabetic (OAD) agents approximately 2 weeks prior to Day -2 admission
- •Females of childbearing potential must have a negative pregnancy test at Screening and on Day -2 admission and must agree to use highly effective contraception methods from Screening throughout study participation and for 14 days following the last dose of study drug.
排除标准
- •History of type 1 diabetes mellitus or secondary forms of diabetes
- •History of acute diabetes complications
- •Recent or significant heart conditions
- •Uncontrolled hypertension
- •QTc interval > 500 msec by ECG at Screening or on Day -2 admission, a personal or family history of QTc prolongation, congenital long QT syndrome, or use of drugs that prolong the QTc interval, such as Class Ia or Class III antiarrhythmic agents, erythromycin, and certain antipsychotics (eg, ziprasidone)
- •History of severe GI disease (e.g., gastroparesis)
- •History of pancreatitis (acute or chronic)
- •Current consumption of > 14 alcoholic drinks per week, or more than 4 alcoholic drinks on any one day
- •Current regular use of tobacco- or nicotine-containing products in excess of 10 cigarettes per day or equivalent
- •History of substance abuse within 12 months prior to Screening
- •Significant hepatic disease, including, but not limited to, chronic active hepatitis and liver cirrhosis (Child-Pugh Class A, B, or C)
- •History of malignancy within 5 years prior to Screening
- •Significant thyroid disease
- •Treatment with selected medications, as indicated in the protocol
- •Prior treatment with open-label ranolazine or known hypersensitivity or intolerance to ranolazine or its excipients
- •Known hypersensitivity or intolerance to GLP-1 mimetics
- •Known hypersensitivity or intolerance to acetaminophen
- •Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 X upper limit of normal (ULN)
- •Total Bilirubin (TB) > 2 mg/dL
- •Hemoglobin < 12 g/dL (for males) or < 11 g/dL (for females)
- •Positive for hepatitis B surface antigen
- •Positive for anti-hepatitis C virus antibody
- •Positive for human immunodeficiency virus-1 (HIV-1) antibody
- •Positive urine drug screen
- •Positive alcohol test
- •Donation of blood or blood products to a blood bank, blood transfusion, or participation in a clinical study requiring withdrawal of > 500 mL of blood during the 6 weeks prior to Screening
- •Females who are pregnant or breastfeeding
- •Other condition(s) that, in the opinion of the investigator, would compromise the safety of the subject, would prevent compliance with the study protocol, or would compromise the quality of the clinical study.
研究组 & 干预措施
Placebo, Ranolazine, Exenatide
Active Comparator
干预措施: Ranolazine (Drug)
Placebo, Ranolazine, Exenatide
Active Comparator
干预措施: Placebo (Drug)
Placebo, Ranolazine, Exenatide
Active Comparator
干预措施: Exenatide (Drug)
Ranolazine, Placebo, Exenatide
Active Comparator
干预措施: Ranolazine (Drug)
Ranolazine, Placebo, Exenatide
Active Comparator
干预措施: Placebo (Drug)
Ranolazine, Placebo, Exenatide
Active Comparator
干预措施: Exenatide (Drug)
结局指标
主要结局
Area under the concentration-time curve (AUC) of plasma glucagon during the standard meal test (SMT)
时间窗: Days 5, 10, and 14
次要结局
- Plasma glucose, serum insulin, and serum C-peptide AUCs during the SMT(Days 5, 10, and 14)
- Collapse under Acetaminophen PK(Days 5 and 10)
- Area under the plasma acetaminophen concentration-time curve from time 0 to 240 min (AUC0-240 min)(Days 5 and 10)
- Collapse all under ranolazine pharmacokinetics (PK)(Days 5 and 10)
- Trough plasma ranolazine concentrations (Ctrough)(Days 5 and 10)
- Average plasma ranolazine concentration during a dosing interval at steady state (Css,ave)(Days 5 and 10)
- Area under the plasma ranolazine concentration-time curve over dosing interval (AUCtau)(Days 5 and 10)
- Apparent elimination half-life (t1/2) of ranolazine(Days 5 and 10)
- Adverse events, physical examinations, clinical laboratory determinations, electrocardiograms (ECG), and vital sign assessments.(From Screening to 7 days after the final dose)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
A Study for Participants With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT00871572Eli Lilly and Company87
已完成
3 期
A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus PatientsDiabetes Mellitus, Type 2Type 2 Diabetes MellitusNCT00349427GlaxoSmithKline256
已完成
1 期
Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 DiabetesDiabetes Mellitus, Type 2NCT01396187Pfizer50
已完成
1 期
Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 DiabetesDiabetes Mellitus, Type 2NCT01285518Pfizer84
已完成
2 期
A Study of LY2409021 in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT01241448Eli Lilly and Company263